Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 29

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Gastric cancer55Bladder cancer54Endometrial cancer53+679

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Gastric cancer+1

Recruiting

Comparing Remimazolam and Propofol for Deep Sedation in Patients Undergoing Endoscopic Ultrasound for Gastric and Pancreatic Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Propofol
  • Sponsor:Ospedale San Raffaele S.r.l.

Neoplasm malignant

Recruiting

A Study of MK-1084 Alone and Combined with Cetuximab for People with Advanced Solid Tumors that Have a KRAS G12C Gene Change

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer

Recruiting

A Study of BNT323 and BNT327 for Patients with Advanced Breast Cancer to Test Safety and Effectiveness

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BNT327
  • Sponsor:BioNTech SE

Endometrial cancer+12

Recruiting

A Study of Zanidatamab for Patients with Previously Treated HER2-Expressing Solid Tumors

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Zanidatamab
  • Sponsor:Jazz Pharmaceuticals Ireland Limited

Prostate cancer

Recruiting

A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Congenital cystic kidney disease

Recruiting

Testing dapagliflozin to slow kidney function decline in patients with autosomal dominant polycystic kidney disease

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Dapagliflozin
  • Sponsor:University Of Cologne

Neoplasm malignant

Recruiting

A study to test the safety and effectiveness of BAY 3713372 alone and with drug combination in patients with MTAP-deleted solid tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Bayer AG

Prostate cancer

Recruiting

Study of xaluritamig plus abiraterone for men with metastatic castration-resistant prostate cancer who have not received chemotherapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Amgen Inc.

Bladder transitional cell carcinoma

Recruiting

A study comparing erdafitinib delivery system to chemotherapy for patients with high-risk non-muscle-invasive bladder cancer who received BCG treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Erdafitinib
  • Sponsor:Janssen Cilag International

Astrocytoma malignant

Recruiting

Vorasidenib for patients with IDH-mutant grade 2 or 3 astrocytoma after completing first-line chemoradiotherapy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Vorasidenib
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Pleural mesothelioma

Recruiting

Study of fianlimab plus cemiplimab with chemotherapy or cemiplimab with chemotherapy for patients with pleural mesothelioma who have not received prior treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Cholangiocarcinoma+1

Recruiting

Testing trifluridine, tipiracil and nanoliposomal irinotecan combination for patients with bile duct or gallbladder cancer after previous treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Irinotecan
  • Sponsor:Heinrich-Heine-Universitaet Duesseldorf

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab462 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsBevacizumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.